Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6784895 | 0.86 | MAOB (0.45) | HTR2AHTR2CTSHRCA12CA1 | |
| SCHEMBL6785437 | 0.80 | CA1 (0.44) | HTR2AHTR2CTSHRSMN1; SMN2CA12 | |
| SCHEMBL5796491 | 0.78 | LMNA (0.55) | TSHRSMN1; SMN2CA1CA2ALDH1A1 | |
| SCHEMBL5823771 | 0.77 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAMAPK1HTT | |
| SCHEMBL14692125 | 0.76 | LMNA (0.56) | TSHRSMN1; SMN2ALDH1A1LMNAHPGD | |
| SCHEMBL8945338 | 0.71 | L3MBTL1 (0.46) | ACHEMAOBMAOABRD4 | |
| SCHEMBL8290792 | 0.70 | MAOB (0.52) | CA12CA1CA2CA9LMNA | |
| SCHEMBL10157718 | 0.70 | HTR2C (0.47) | HTR2AHTR2CTSHRCA12CA1 | |
| SCHEMBL8944942 | 0.70 | L3MBTL1 (0.44) | ACHEMAOBMAOA | |
| SCHEMBL16981016 | 0.68 | TTR (0.51) | TSHRSMN1; SMN2LMNAHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615636-A1 | BICYCLIC COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089366-A1 | BICYCLIC COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER JAPAN, INC. (JP) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204409-A1 | Bicyclic compounds as NR2B receptor antagonists | ANDO KAZUO (JP) | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204409-A1 | Bicyclic compounds as NR2B receptor antagonists | GRIN1, GRIN2B, GRIN2A | HTR2A 313/4885HTR2C 271/4885TSHR 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.